Investment Thesis
KALA Bio exhibits critical operational and financial stress with zero revenue generation, indicating failed or stalled product commercialization despite being in the pharmaceutical sector. The company is burning $4.4M annually in free cash flow while carrying $26.9M in long-term debt against only $12.3M in total assets, creating severe solvency risk with negative interest coverage and minimal cash cushion of $1.8M.
Strengths
- Strong short-term liquidity with 7.91x current ratio providing runway for near-term obligations
- Positive stockholders equity of $10.8M despite losses
- Recent financial data available (March 31, 2026) enables current assessment
Risks
- Zero revenue suggests failed product commercialization or pre-commercial stage despite mature pharmaceutical company classification
- Debt-to-equity ratio of 2.50x with total debt exceeding total assets creates insolvency risk and refinancing pressure
- Negative operating and free cash flow of -$2.9M and -$4.4M respectively with no revenue growth path visible
- Negative interest coverage ratio of -1.2x indicates inability to service debt from operations
- Zero insider Form 4 filings in 90 days suggests lack of management confidence
Key Metrics to Watch
- Cash burn rate and runway to potential insolvency or financing event
- Revenue achievement from pipeline products or partnership announcements
- Debt restructuring, refinancing activity, or equity raise announcements
Financial Metrics
Revenue
0.0
Net Income
-1.6M
EPS (Diluted)
$-0.14
Free Cash Flow
-4.4M
Total Assets
12.3M
Cash
1.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-15.1%
ROA
-13.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
7.91x
Quick Ratio
7.91x
Debt/Equity
2.50x
Debt/Assets
12.6%
Interest Coverage
-1.24x
Long-term Debt
26.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:14:00.533399 |
Data as of: 2026-03-31 |
Powered by Claude AI